Reduced plasma levels of coagulation factors in relation to prostate cancer

被引:7
作者
Beecken, WD
Bentas, W
Engels, K
Glienke, W
Urbschat, A
Jonas, D
Binder, J
Scharrer, I
机构
[1] Univ Frankfurt, Klin Urol & Kinderurol, D-60590 Frankfurt, Germany
[2] Univ Frankfurt, Inst Pathol, D-60590 Frankfurt, Germany
[3] Univ Frankfurt, Clin Hemostaseol, D-60590 Frankfurt, Germany
关键词
antithrombin; plasminogen; plasminogen activator inhibitor-1; heparin cofactor II; angiogenesis;
D O I
10.1002/pros.10142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate cancer has historically been associated with coagulation abnormalities. This study was undertaken to investigate the prevalence of abnormalities of coagulation factors in patients with prostate cancer before and after radical prostatectomy (RP). Because coagulation factors have been shown to be involved in tumor angiogenesis, the vascular density of the prostate tumors was assessed. METHODS. Plasma of 40 consecutive patients with histologically proven prostate cancer was investigated pre-RP and post-RP. The antigen level for antithrombin, plasminogen activator inhibitor-1, and heparin cofactor-II, and the plasma activity of antithrombin and plasminogen were determined by using immunologic and chromogenic assays. The values of these assays were compared with a group of 28 male, age-matched patients without any evidence of cancer and 18 patients with orthopedic interventions preoperatively and postoperatively. The vascular density of the prostate tumors was assessed by staining paraffin sections with an antibody to CD34. RESULTS. The median plasma antigen levels and/or activities of the investigated factors were below normal in the prostate cancer patients before RP. Furthermore, coagulation factors were significantly lower than in the age-matched control group and patients before and after orthopedic surgery. In prostate cancer patients, the median values of all investigated factors went up to normal levels within 2 weeks after RP, whereas postsurgical levels in orthopedic patients remained stable. No correlations to tumor parameters have been observed. CONCLUSION. We assume that the reduction of these coagulation factors is a principle concept in prostate cancer that needs further investigation. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:160 / 167
页数:8
相关论文
共 34 条
[1]   PROCOAGULANT PROPERTIES OF BENIGN AND MALIGNANT PROSTATIC TISSUE [J].
ADAMSON, AS ;
FRANCIS, JL ;
WITHEROW, RON ;
SNELL, ME .
BRITISH JOURNAL OF UROLOGY, 1994, 74 (02) :204-209
[2]   Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors [J].
Bhatti, RA ;
Gadarowski, JJ ;
Ray, PS .
TUMOR BIOLOGY, 1997, 18 (01) :1-5
[3]  
Bhatti RA, 1996, INVAS METAST, V16, P49
[4]   The hemostatic system as a regulator of angiogenesis [J].
Browder, T ;
Folkman, J ;
Pirie-Shepherd, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (03) :1521-1524
[5]  
COLUCCI M, 1981, BLOOD, V57, P733
[6]   CLOTTING PREDISPOSITION IN CARCINOMA OF THE PROSTATE [J].
DOBBS, RM ;
BARBER, JA ;
WEIGEL, JW ;
BERGIN, JE .
JOURNAL OF UROLOGY, 1980, 123 (05) :706-709
[7]  
DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
[8]   TUMOR SHEDDING AND COAGULATION [J].
DVORAK, HF ;
QUAY, SC ;
ORENSTEIN, NS ;
DVORAK, AM ;
HAHN, P ;
BITZER, AM ;
CARVALHO, AC .
SCIENCE, 1981, 212 (4497) :923-924
[9]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND PROGNOSIS IN PRIMARY BREAST-CANCER [J].
FOEKENS, JA ;
SCHMITT, M ;
VANPUTTEN, WLJ ;
PETERS, HA ;
KRAMER, MD ;
JANICKE, F ;
KLIJN, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1648-1658
[10]  
FOLKMAN J, 1989, J NATL CANCER I, V82, P4